TP53 and endometrial cancer: Its anticancer effect was linked to inducing G2/M cell cycle arrest by upregulating p53 and p21 proteins, thereby inhibiting cancer cell proliferation [18] Further studies on drug-resistant endometrial cancer cells revealed that compound 1 exerts its anticancer effects through multiple mechanisms, including the inhibition of topoisomerase I and II, which are essential for DNA replication and cell division, thus hindering cancer cell growth.